China Lymphoma Patient Registry Study
China Lymphoma Patient Registry Study
Lymphoma is the most common hematologic tumor. It is derived from lymphoid tissue, including
 Hodgkin's lymphoma(HL) and non Hodgkin's lymphoma(NHL). The treatment of lymphoma includes
 chemotherapy, radiotherapy, stem cell transplantation, targeted therapy and surgery etc. With
 the progress of treatment, the survival rate of lymphoma patients has been improved. But the
 5 year survival rate of lymphoma in China is shorter than that in United States. The reason
 is that there is still a gap between China and the United States in disease screening,
 diagnosis and treatment.

 Observational studies, especially cohort studies, are important tools for understanding
 disease progression, treatment, and prognosis in the real world. Observational cohort studies
 which involve over 500 patients are currently launched by South Korea and the United States.
 China, which has more patients, doesn't have a cohort of patients with lymphoma. So the
 primary objective of this study was to establish an observational cohort of patients with
 lymphoma in China and follow up the patients for a long period of time to provide basic
 support for clinical research and drug development, and continuously improve patient outcomes
 and quality of life. The secondary objective is to collect information about diagnosis,
 treatment, follow-up and prognosis of lymphoma.
Lymphoma is the most common hematologic tumor. It is derived from lymphoid tissue, including
 Hodgkin's lymphoma(HL) and non Hodgkin's lymphoma(NHL). The treatment of lymphoma includes
 chemotherapy, radiotherapy, stem cell transplantation, targeted therapy and surgery etc. With
 the progress of treatment, the survival rate of lymphoma patients has been improved. But the
 5 year survival rate of lymphoma in China is shorter than that in United States. The reason
 is that there is still a gap between China and the United States in disease screening,
 diagnosis and treatment.

 Observational studies, especially cohort studies, are important tools for understanding
 disease progression, treatment, and prognosis in the real world. Observational cohort studies
 which involve over 500 patients are currently launched by South Korea and the United States.
 China, which has more patients, doesn't have a cohort of patients with lymphoma. So the
 primary objective of this study was to establish an observational cohort of patients with
 lymphoma in China and follow up the patients for a long period of time to provide basic
 support for clinical research and drug development, and continuously improve patient outcomes
 and quality of life. The secondary objective is to collect information about diagnosis,
 treatment, follow-up and prognosis of lymphoma.
Inclusion Criteria:

 -  The disease was diagnosed by Hodgkin's or non Hodgkin's lymphoma

 -  18 years of age or older at diagnosis

 -  The diagnosis was confirmed within 6 months before admission

 -  Informed consent was obtained

 Exclusion Criteria:

 -  There are no special exclusion criteria in this study